Genetically Engineered T Cells for Niche Environments

The present inventive concept relates to genetically engineered T cells with Regnase-1 and/or TGFBRII disruption, adapted for specific, narrow markets or unique operational environments, such as high-security needs, disaster relief, extreme weather conditions, remote areas, high-altitude environments, and extreme cold environments.

While the original patent disclosed genetically engineered T cells with Regnase-1 and/or TGFBRII disruption for improved functionality and persistence, these cells may not be suitable for operation in specialized environments. The present inventive concept addresses this limitation by adapting the genetically engineered T cells to resist radiation damage, survive in extreme weather conditions, grow in low-resource settings, adapt to low-oxygen conditions, and function in temperatures below -20°C.

The present inventive concept comprises genetically engineered T cells with Regnase-1 and/or TGFBRII disruption, further engineered to resist radiation damage, survive in extreme weather conditions, grow in low-resource settings, adapt to low-oxygen conditions, and function in temperatures below -20°C. The T cells are designed to operate in high-security environments, disaster relief scenarios, remote areas, high-altitude environments, and extreme cold environments. The inventive concept includes various embodiments, such as systems for CAR-T cell therapy, methods for generating CAR-T cells, and genetically engineered T cells for treating cancer in specialized environments.

The present inventive concept is novel and non-obvious in that it adapts the genetically engineered T cells with Regnase-1 and/or TGFBRII disruption to specific, narrow markets or unique operational environments, thereby providing a unique solution for these environments. The inventive concept's novelty and inventive step reside in the specific combinations of genetic modifications and environmental adaptations, which are not obvious from the original patent.

Alternative embodiments of the inventive concept may include additional genetic modifications, such as editing TRAC and/or β2M genes, or using different gene editing systems, such as CRISPR/Cas-mediated gene editing. Variations of the inventive concept may include adapting the genetically engineered T cells to other specialized environments, such as space exploration or underwater operations.

The present inventive concept has significant commercial potential in the fields of immunotherapy, cancer treatment, and biotechnology. The target industries include pharmaceutical companies, biotech startups, and research institutions focused on developing novel therapies for cancer and other diseases.